Status: FDA investigation closed 2023 without conclusive causal finding; clinical signal sustained the methodology concern. In July 2018, the FDA’s Center for Veterinary Medicine opened a formal investigation of dilated cardiomyopathy (DCM) in dogs eating grain-free formulations — pet foods using legumes (peas, lentils, chickpeas, beans) and/or potatoes as principal carbohydrate sources instead of grains. By the time the FDA closed the investigation in 2023 without conclusive causal finding, more than 1,100 canine DCM cases had been reported through the FDA Safety Reporting Portal, with epidemiological signal pointing toward grain-free formulations using legume-heavy ingredient stacks. The 2018 FDA update named 16 brands with the highest reported case counts (Acana, Zignature, Taste of the Wild, 4Health, Earthborn Holistic, Blue Buffalo, Nature’s Domain, Fromm, Merrick, California Natural, Natural Balance, Orijen, Nature’s Variety, NutriSource, Nutro, Rachael Ray Nutrish). The investigation was substantially closed because the causal mechanism could not be conclusively isolated.

What was recalled

This page covers the FDA’s grain-free dog food and dilated cardiomyopathy (DCM) investigation, a major regulatory event that did not produce specific brand recalls but substantially reshaped industry formulation practices and consumer awareness. The investigation opened in July 2018 following a clinical signal noted by board-certified veterinary cardiologists: a cluster of DCM cases in breeds not typically genetically predisposed to the condition (Golden Retrievers, Doberman Pinschers, Boxers being the genetically-predisposed reference; the new cluster involved Goldens at higher-than-baseline rates plus breeds like Whippets, Shih Tzus, Bulldog crosses, and mixed-breed dogs not previously associated with DCM).

FDA collected reports through the Safety Reporting Portal and worked with veterinary cardiology specialists and Vet-LIRN member labs to characterize the cases. The 2018 update named 16 brands by reported-case-count frequency, the largest cluster centered on Acana and Zignature. The 2019 FDA update added additional brands. Multiple veterinary cardiology peer-reviewed studies in 2018-2022 documented case series of DCM reversal after dietary change away from grain-free formulations — producing the strongest mechanistic evidence linking the formulation pattern to the disease. The 2023 FDA closure acknowledged the clinical signal but cited insufficient mechanistic evidence to conclusively identify a single causal nutrient or ingredient.

Why it was recalled

The hypothesized causal mechanism for grain-free DCM has evolved across multiple iterations. Early hypotheses focused on taurine deficiency — legume-heavy formulations may interfere with taurine synthesis or absorption in some breeds. Subsequent research showed that taurine deficiency does not explain all cases; many affected dogs had normal whole-blood taurine levels. Later hypotheses focused on the legume ingredient stack itself — peas, lentils, chickpeas as principal carbohydrate sources may produce subtle metabolic effects (altered amino acid availability, bioactive compounds, intestinal absorption interactions) that converge on cardiac function over months to years of feeding.

The clinical signature is consistent: affected dogs develop echocardiographic left ventricular dilation and reduced fractional shortening, sometimes progressing to congestive heart failure (CHF) and death. Case-series evidence documents partial-to-full echocardiographic reversal after dietary change away from grain-free formulations — the strongest mechanistic indicator that the formulation pattern is causally involved. The 2023 FDA closure without conclusive finding reflects the difficulty of conclusively establishing causation in observational data: definitive proof would require a randomized controlled trial feeding grain-free vs. grain-inclusive formulations to large cohorts of dogs over years, which is operationally infeasible. The 2018-2023 investigation drove substantial industry reformulation: many premium pet food brands either reduced legume density, added grains back into formulations, or supplemented with taurine. The FDA investigation archive documents the regulatory record.

Health risks for your pet

Dilated cardiomyopathy (DCM) in dogs is a serious cardiac disease characterized by weakening and enlargement of the heart muscle, leading to reduced contractility, ventricular dilation, and eventually congestive heart failure. Clinical signs include exercise intolerance, coughing, increased respiratory rate, lethargy, weight loss, and sudden collapse. Diagnostic workup involves echocardiography (the definitive test), thoracic radiographs, and serum cardiac biomarker testing (NT-proBNP, troponin I). Severity ranges from subclinical echocardiographic changes detected during screening of at-risk breeds to end-stage congestive heart failure. Treatment for established DCM involves diuretics, ACE inhibitors, pimobendan, and antiarrhythmic medications, with long-term prognosis depending on the underlying etiology. Dietary-associated DCM has shown partial-to-full echocardiographic reversal after dietary change in case series — a distinct prognostic feature compared to genetic DCM, which is progressive and irreversible.

What to do if you bought affected product

If you currently feed grain-free dog food formulated with legumes (peas, lentils, chickpeas) or potatoes as principal carbohydrate sources, the actionable considerations are: (1) Discuss with your veterinarian whether echocardiographic screening is appropriate for your dog — particularly if the dog is medium or large breed and has been on grain-free formulation for 12+ months. NT-proBNP serum testing is a less expensive screening alternative. (2) Consider transitioning to a grain-inclusive formulation if your dog is from a DCM-susceptible breed or has been on grain-free for an extended period. The FDA investigation did not identify all grain-free formulations as risk-equivalent; some brands reformulated post-2018 to reduce legume density. (3) If your dog develops exercise intolerance, coughing, or unexplained lethargy, contact your veterinarian for cardiac evaluation. The KibbleIQ analyzer applies a legume-density penalty in our dry-kibble rubric (v15) for formulations with pea-derived ingredients in the top 5 or multi-legume stacks in the top 8 — this scoring reflects the FDA investigation findings.

How this affects KibbleIQ’s grade

The 16 brands named in the 2018 FDA update (Acana, Zignature, Taste of the Wild, 4Health, Earthborn Holistic, Blue Buffalo, Nature’s Domain, Fromm, Merrick, California Natural, Natural Balance, Orijen, Nature’s Variety, NutriSource, Nutro, Rachael Ray Nutrish) are largely scored in the KibbleIQ database on their current ingredient lists per our published methodology. The KibbleIQ dry-kibble rubric (v15) explicitly includes a legume-density penalty aligned with the FDA investigation findings: -5 points for pea-derived ingredients in the top 5 positions, and -6 points for multi-legume stacks (3+ legume forms) in the top 8 positions. This scoring approach reflects the strongest available mechanistic evidence from veterinary cardiology peer-reviewed literature. Several scored brands (Acana Singles Duck, Zignature LID, Wholehearted, 4Health Salmon Potato GF) have received tier adjustments under the legume-density penalty since its 2026-04 implementation. Recall-history scoring under our planned methodology v2 will treat the grain-free DCM cluster as a category-wide formulation concern rather than a per-brand recall event, since no individual brand recalls were issued.